Have been watching this story develop for the better part of 8 years. They have had a lot of the typical small company fits and starts with development of new products, manufacturing yield, etc etc etc. Management has been methodical in moving the company forward and I would characterize them as very realistic. After all that time, it finally seems as though...
Semler Scientific (SMLR) is disrupting the Peripheral Arterial Disease(PAD) diagnostics market with their QuantaFlo test offering a mobile, high-value, faster, cheaper, and more accurate in-office test that can be performed by your primary care physician or even a medical aid. Semler has been growing revenues north of 30% annually and that will continue for the...
Been following this company's progress for over ten years. It is truly remarkable what they have been through to get to where they are now. Bottomline, Vascepa is a blockbuster in the making with incredibly compelling and unprecedented outcomes based clinical trial results which will make this standard of care to a large subset of our population. What is even...
OCUL has had many difficulties over the past number of years, but finally, after shaking up management, getting over manufacturing and regulatory hurdles, and now receiving a broadened label and clarity on reimbursement the stock looks like a screaming buy. While it is always tricky to invest when a biopharma company is going through a product launch, it would...
